Symbols / GRI
GRI Chart
About
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.47M |
| Enterprise Value | -4.69M | Income | -11.96M | Sales | — |
| Book/sh | 12.07 | Cash/sh | 5.70 | Dividend Yield | — |
| Payout | 0.00% | Employees | 3 | IPO | — |
| P/E | — | Forward P/E | -0.19 | PEG | — |
| P/S | — | P/B | 0.20 | P/C | — |
| EV/EBITDA | 0.39 | EV/Sales | — | Quick Ratio | 3.11 |
| Current Ratio | 3.25 | Debt/Eq | 1.18 | LT Debt/Eq | — |
| EPS (ttm) | -121.80 | EPS next Y | -12.60 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-01-30 07:00 | ROA | -103.93% |
| ROE | -238.17% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.45M |
| Shs Float | 1.45M | Short Float | 10.25% | Short Ratio | 0.18 |
| Short Interest | — | 52W High | 311.36 | 52W Low | 2.10 |
| Beta | -1.23 | Avg Volume | 403.79K | Volume | 34.63K |
| Target Price | $644.00 | Recom | None | Prev Close | $2.33 |
| Price | $2.40 | Change | 3.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$644.00
Mean price target
2. Current target
$2.40
Latest analyst target
3. DCF / Fair value
$-68.12
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.40
Low
$280.00
High
$1008.00
Mean
$644.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-08 | main | Ascendiant Capital | Buy → Buy | $36 |
| 2025-09-22 | main | Ascendiant Capital | Buy → Buy | $35 |
| 2025-06-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-05-27 | main | Ascendiant Capital | Buy → Buy | $34 |
| 2025-04-14 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-12-09 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2024-12-05 | main | Ascendiant Capital | Buy → Buy | $13 |
News
RSS: Latest GRI news- GRI Bio Announces Reverse Stock Split To Regain Minimum Bid Price Nasdaq Compliance - Nasdaq hu, 22 Jan 2026 08
- Grainger (LON:GRI) Stock Price Passes Above 200-Day Moving Average - Here's Why - MarketBeat hu, 19 Feb 2026 09
- GRI Bio stock soars after gene data shows IPF drug targets disease drivers - Investing.com Wed, 28 Jan 2026 08
- GRI Bio, Inc. Discusses Positive Phase 2a Data in Idiopathic Pulmonary Fibrosis During Virtual Investor Segment - Quiver Quantitative ue, 17 Feb 2026 14
- GRI Bio slashes share count with 1-for-28 split to meet Nasdaq price rule - Stock Titan Wed, 21 Jan 2026 08
- GRI touts IPF safety edge, lung function gains amid cash crunch - Fierce Biotech hu, 11 Dec 2025 08
- GRI Bio Expands At-The-Market Equity Offering Capacity - TipRanks Fri, 30 Jan 2026 08
- GRI Bio Announces Reverse Stock Split - GlobeNewswire Wed, 21 Jan 2026 08
- GRI Bio's Price Target Raised by Ascendiant Capital | GRI Stock News - GuruFocus Mon, 22 Sep 2025 07
- GRI Bio (GRI) Price Target Increased by 2,700.00% to 656.88 - Nasdaq Wed, 04 Feb 2026 08
- GRI Bio Reports Positive Study Results For Chronic Lung Disease, But Stock Slumps 20% — What Happened? - Stocktwits Wed, 28 Jan 2026 08
- GRI Bio shareholders approve reverse stock split and report Nasdaq compliance - Investing.com hu, 15 Jan 2026 08
- GRI Bio, Inc. Reports Strong Cash Position and Positive Phase 2a Results for GRI-0621 in Pulmonary Fibrosis - Quiver Quantitative Wed, 04 Feb 2026 08
- GRI Bio (NASDAQ: GRI) unveils Phase 2a IPF results showing favorable safety and collagen biomarker shifts - Stock Titan Wed, 10 Dec 2025 08
- Robert Hudson Purchases 77 Shares of Grainger (LON:GRI) Stock - MarketBeat Wed, 04 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -11.97M | -8.23M | -10.95M | -2.24M |
| TotalUnusualItems | 182.00K | -325.00K | 50.00K | |
| TotalUnusualItemsExcludingGoodwill | 182.00K | -325.00K | 50.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -11.96M | -8.21M | -13.04M | -3.22M |
| ReconciledDepreciation | 4.00K | 4.00K | 4.00K | 3.00K |
| EBITDA | -11.97M | -8.23M | -10.95M | -2.56M |
| EBIT | -11.98M | -8.23M | -10.96M | -2.56M |
| NetInterestIncome | 21.00K | 25.00K | -2.08M | -653.00K |
| InterestExpense | 2.08M | 653.00K | 547.00K | |
| InterestIncome | 21.00K | 25.00K | ||
| NormalizedIncome | -11.96M | -8.21M | -13.04M | -2.89M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -11.96M | -8.21M | -13.04M | -3.22M |
| TotalExpenses | 11.98M | 8.23M | 11.39M | 2.24M |
| TotalOperatingIncomeAsReported | -11.98M | -8.23M | -11.39M | -2.24M |
| DilutedAverageShares | 98.16K | 6.55K | 104.00 | 68.00 |
| BasicAverageShares | 98.16K | 6.55K | 104.00 | 68.00 |
| DilutedEPS | -121.80 | -1.55K | -125.36K | -47.31K |
| BasicEPS | -121.80 | -1.55K | -125.36K | -47.31K |
| DilutedNIAvailtoComStockholders | -11.96M | -10.12M | -13.04M | -3.22M |
| NetIncomeCommonStockholders | -11.96M | -10.12M | -13.04M | -3.22M |
| OtherunderPreferredStockDividend | 0.00 | 1.91M | ||
| NetIncome | -11.96M | -8.21M | -13.04M | -3.22M |
| NetIncomeIncludingNoncontrollingInterests | -11.96M | -8.21M | -13.04M | -3.22M |
| NetIncomeContinuousOperations | -11.96M | -8.21M | -13.04M | -3.22M |
| PretaxIncome | -11.96M | -8.21M | -13.04M | -3.22M |
| OtherIncomeExpense | 3.00K | 432.00K | -325.00K | 50.00K |
| OtherNonOperatingIncomeExpenses | 3.00K | 432.00K | ||
| SpecialIncomeCharges | 0.00 | -325.00K | 50.00K | |
| OtherSpecialCharges | 325.00K | -50.00K | ||
| GainOnSaleOfSecurity | 182.00K | |||
| NetNonOperatingInterestIncomeExpense | 21.00K | 25.00K | -2.08M | -653.00K |
| InterestExpenseNonOperating | 2.08M | 653.00K | 547.00K | |
| InterestIncomeNonOperating | 21.00K | 25.00K | ||
| OperatingIncome | -11.98M | -8.23M | -11.39M | -2.24M |
| OperatingExpense | 11.98M | 8.23M | 11.39M | 2.24M |
| ResearchAndDevelopment | 6.82M | 3.77M | 3.23M | 242.00K |
| SellingGeneralAndAdministration | 5.16M | 4.47M | 8.15M | 2.00M |
| GeneralAndAdministrativeExpense | 5.16M | 4.47M | 8.15M | 2.00M |
| OtherGandA | 5.16M | 4.47M | 8.15M | 2.00M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 361.47K | 18.77K | 104.00 | 68.00 |
| ShareIssued | 361.47K | 18.77K | 104.00 | 68.00 |
| NetDebt | 593.00K | 3.41M | ||
| TotalDebt | 71.00K | 119.00K | 14.00K | 673.00K |
| TangibleBookValue | 6.01M | 4.03M | 259.00K | -1.62M |
| InvestedCapital | 6.01M | 4.03M | 259.00K | -1.02M |
| WorkingCapital | 5.95M | 3.98M | 237.00K | -1.68M |
| NetTangibleAssets | 6.01M | 4.03M | 259.00K | -1.62M |
| CapitalLeaseObligations | 71.00K | 119.00K | 14.00K | 71.00K |
| CommonStockEquity | 6.01M | 4.03M | 259.00K | -1.62M |
| TotalCapitalization | 6.01M | 4.03M | 259.00K | -1.62M |
| TotalEquityGrossMinorityInterest | 6.01M | 4.03M | 259.00K | -1.62M |
| StockholdersEquity | 6.01M | 4.03M | 259.00K | -1.62M |
| RetainedEarnings | -51.70M | -39.74M | -31.53M | -18.50M |
| AdditionalPaidInCapital | 57.70M | 43.77M | 31.79M | 16.87M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.66M | 1.71M | 2.70M | 2.01M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 15.00K | 71.00K | 0.00 | 14.00K |
| LongTermDebtAndCapitalLeaseObligation | 15.00K | 71.00K | 0.00 | 14.00K |
| LongTermCapitalLeaseObligation | 15.00K | 71.00K | 0.00 | 14.00K |
| CurrentLiabilities | 2.64M | 1.64M | 2.70M | 1.99M |
| OtherCurrentLiabilities | 3.00K | |||
| CurrentDeferredLiabilities | 0.00 | 5.00K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 56.00K | 48.00K | 14.00K | 659.00K |
| CurrentCapitalLeaseObligation | 56.00K | 48.00K | 14.00K | 57.00K |
| CurrentDebt | 602.00K | 3.50M | ||
| OtherCurrentBorrowings | 3.50M | |||
| CurrentNotesPayable | 0.00 | 602.00K | 0.00 | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 33.00K | 142.00K | ||
| PayablesAndAccruedExpenses | 2.59M | 1.59M | 2.68M | 1.33M |
| CurrentAccruedExpenses | 750.00K | 691.00K | 1.27M | 36.00K |
| InterestPayable | 0.00 | 1.11M | ||
| Payables | 1.84M | 897.00K | 1.41M | 1.29M |
| AccountsPayable | 1.84M | 897.00K | 1.41M | 1.29M |
| TotalAssets | 8.67M | 5.74M | 2.96M | 383.00K |
| TotalNonCurrentAssets | 74.00K | 124.00K | 22.00K | 71.00K |
| NonCurrentPrepaidAssets | 4.00K | 5.00K | ||
| NetPPE | 74.00K | 124.00K | 22.00K | 71.00K |
| AccumulatedDepreciation | -34.00K | -30.00K | -26.00K | -22.00K |
| GrossPPE | 108.00K | 154.00K | 48.00K | 93.00K |
| OtherProperties | 71.00K | 120.00K | 14.00K | 67.00K |
| MachineryFurnitureEquipment | 37.00K | 34.00K | 34.00K | 26.00K |
| CurrentAssets | 8.59M | 5.62M | 2.93M | 312.00K |
| OtherCurrentAssets | 363.00K | 587.00K | 1.13M | 303.00K |
| CashCashEquivalentsAndShortTermInvestments | 8.23M | 5.03M | 1.81M | 9.00K |
| CashAndCashEquivalents | 8.23M | 5.03M | 1.81M | 9.00K |
| CashFinancial | 8.23M | 5.03M | 1.81M | 9.00K |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -10.19M | -8.61M | -9.00M | -1.09M |
| RepurchaseOfCapitalStock | -1.00K | -1.00K | 0.00 | -124.00K |
| RepaymentOfDebt | 0.00 | -250.00K | 0.00 | |
| IssuanceOfDebt | 0.00 | 1.25M | 1.50M | 500.00K |
| IssuanceOfCapitalStock | 15.56M | 13.10M | 12.25M | 0.00 |
| CapitalExpenditure | -3.00K | -8.00K | -3.00K | |
| InterestPaidSupplementalData | 0.00 | 33.00K | 0.00 | |
| EndCashPosition | 8.23M | 5.03M | 1.81M | 9.00K |
| BeginningCashPosition | 5.03M | 1.81M | 9.00K | 90.00K |
| ChangesInCash | 3.20M | 3.22M | 1.80M | -81.00K |
| FinancingCashFlow | 13.39M | 11.83M | 10.80M | 1.01M |
| CashFlowFromContinuingFinancingActivities | 13.39M | 11.83M | 10.80M | 1.01M |
| NetOtherFinancingCharges | -2.17M | -2.03M | -2.71M | -119.00K |
| ProceedsFromStockOptionExercised | 0.00 | 762.00K | 12.00K | 0.00 |
| NetCommonStockIssuance | 15.56M | 13.10M | 12.25M | -124.00K |
| CommonStockPayments | -1.00K | -1.00K | 0.00 | -124.00K |
| CommonStockIssuance | 15.56M | 13.10M | 12.25M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 1.25M | 1.25M | 500.00K |
| NetShortTermDebtIssuance | 0.00 | 1.25M | 1.25M | 500.00K |
| ShortTermDebtPayments | 0.00 | -250.00K | 0.00 | |
| ShortTermDebtIssuance | 0.00 | 1.25M | 1.50M | 500.00K |
| NetLongTermDebtIssuance | 1.25M | |||
| LongTermDebtPayments | -125.00K | |||
| LongTermDebtIssuance | 1.38M | |||
| InvestingCashFlow | -3.00K | 0.00 | -8.00K | -3.00K |
| CashFlowFromContinuingInvestingActivities | -3.00K | 0.00 | -8.00K | -3.00K |
| NetPPEPurchaseAndSale | -3.00K | 0.00 | -8.00K | -3.00K |
| PurchaseOfPPE | -3.00K | 0.00 | -8.00K | -3.00K |
| OperatingCashFlow | -10.19M | -8.61M | -8.99M | -1.08M |
| CashFlowFromContinuingOperatingActivities | -10.19M | -8.61M | -8.99M | -1.08M |
| ChangeInWorkingCapital | 925.00K | -448.00K | 1.68M | 1.51M |
| ChangeInOtherCurrentLiabilities | -48.00K | 105.00K | -57.00K | -43.00K |
| ChangeInPayablesAndAccruedExpense | 722.00K | -866.00K | 2.28M | 1.59M |
| ChangeInAccruedExpense | 59.00K | -479.00K | 125.00K | 696.00K |
| ChangeInPayable | 663.00K | -387.00K | 2.16M | 897.00K |
| ChangeInAccountPayable | 663.00K | -387.00K | 2.16M | 897.00K |
| ChangeInPrepaidAssets | 251.00K | 313.00K | -547.00K | -35.00K |
| OtherNonCashItems | 48.00K | -105.00K | 2.16M | 217.00K |
| StockBasedCompensation | 793.00K | 148.00K | 388.00K | 25.00K |
| AssetImpairmentCharge | 53.00K | 47.00K | ||
| DepreciationAmortizationDepletion | 4.00K | 4.00K | 4.00K | 3.00K |
| DepreciationAndAmortization | 4.00K | 4.00K | 4.00K | 3.00K |
| Depreciation | 4.00K | 4.00K | 4.00K | 3.00K |
| OperatingGainsLosses | -3.00K | -182.00K | 325.00K | -50.00K |
| GainLossOnInvestmentSecurities | -3.00K | -182.00K | ||
| NetIncomeFromContinuingOperations | -11.96M | -8.21M | -13.04M | -3.22M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GRI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|